MX2016016339A - Adjuvant composition comprising a growth factor and a neuropeptide for accelerating wound healing and organ re-epithelisation. - Google Patents

Adjuvant composition comprising a growth factor and a neuropeptide for accelerating wound healing and organ re-epithelisation.

Info

Publication number
MX2016016339A
MX2016016339A MX2016016339A MX2016016339A MX2016016339A MX 2016016339 A MX2016016339 A MX 2016016339A MX 2016016339 A MX2016016339 A MX 2016016339A MX 2016016339 A MX2016016339 A MX 2016016339A MX 2016016339 A MX2016016339 A MX 2016016339A
Authority
MX
Mexico
Prior art keywords
growth factor
organ
epithelisation
neuropeptide
wound healing
Prior art date
Application number
MX2016016339A
Other languages
Spanish (es)
Inventor
Rodríguez Rojas Rafael
Original Assignee
Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A S De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A S De C V filed Critical Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A S De C V
Priority to MX2016016339A priority Critical patent/MX2016016339A/en
Priority to PCT/IB2017/057673 priority patent/WO2018104874A1/en
Publication of MX2016016339A publication Critical patent/MX2016016339A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

The invention relates to the pharmaceutical and biotechnology industry for wound healing and organ re-epithelisation treatments. The advantages of the invention with respect to compositions of the prior art are that, in addition to accelerating the healing process, the composition makes it possible to speed up organ re-epithelisation without generating hyperplasia, thereby improving organ quality following a deterioration. The composition is formed by a growth factor and a neuropeptide. The growth factor is epidermal growth factor, while the neuropeptide is neurotensin. The composition contains epidermal growth factor in a concentration of 0.00001-10 mg/ml and neurotensin in a concentration of 0.00001-10 mg/ml. The combination can have any pharmaceutical form and can be administered by any route of administration.
MX2016016339A 2016-12-09 2016-12-09 Adjuvant composition comprising a growth factor and a neuropeptide for accelerating wound healing and organ re-epithelisation. MX2016016339A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2016016339A MX2016016339A (en) 2016-12-09 2016-12-09 Adjuvant composition comprising a growth factor and a neuropeptide for accelerating wound healing and organ re-epithelisation.
PCT/IB2017/057673 WO2018104874A1 (en) 2016-12-09 2017-12-06 Adjuvant composition comprising a growth factor and a neuropeptide for accelerating wound healing and organ re-epithelisation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2016016339A MX2016016339A (en) 2016-12-09 2016-12-09 Adjuvant composition comprising a growth factor and a neuropeptide for accelerating wound healing and organ re-epithelisation.

Publications (1)

Publication Number Publication Date
MX2016016339A true MX2016016339A (en) 2018-06-08

Family

ID=62491777

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016339A MX2016016339A (en) 2016-12-09 2016-12-09 Adjuvant composition comprising a growth factor and a neuropeptide for accelerating wound healing and organ re-epithelisation.

Country Status (2)

Country Link
MX (1) MX2016016339A (en)
WO (1) WO2018104874A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116606861A (en) 2016-06-07 2023-08-18 摩登纳特斯有限公司 Modified RNAs encoding VEGF-A polypeptides, formulations and uses thereof
KR20200081420A (en) 2017-10-31 2020-07-07 모더나티엑스, 인크. Lipid nanoparticles for carrying modified RNA encoding VEGF-A polypeptide
EP3965797A1 (en) * 2019-05-08 2022-03-16 AstraZeneca AB Compositions for skin and wounds and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2210727T3 (en) * 1998-03-07 2004-07-01 Daewoong Pharmaceutical Co., Ltd. TOPICAL COMPOSITION CONTAINING HUMAN EPIDERMIC GROWTH FACTOR.
HK1077740A1 (en) * 2001-12-20 2006-02-24 Ct Ingenieria Genetica Biotech Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation
US7776815B2 (en) * 2004-02-24 2010-08-17 Wisconsin Alumni Research Foundation Use of neuropeptides for ligament healing
CU23388B6 (en) * 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech PHARMACEUTICAL COMPOSITION OF MICROSPHERES TO PREVENT AMPUTATION OF THE DIABETIC FOOT

Also Published As

Publication number Publication date
WO2018104874A1 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
PH12018502634A1 (en) Topical compositions of apremilast
NZ734516A (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n’-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
MX2019003397A (en) Methods of treating mitochondrial and metabolic disorders.
MX2020013557A (en) A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof.
NZ712270A (en) Pharmaceutical composition of s-ketamine hydrochloride
MX2017015879A (en) Hydroxypropyl beta-cyclodextrin compositions and methods.
MX2016016339A (en) Adjuvant composition comprising a growth factor and a neuropeptide for accelerating wound healing and organ re-epithelisation.
CL2018003178A1 (en) Pharmaceutical composition
SG10201806854XA (en) Compositions comprising 15-ohepa and methods of using the same
EA201791537A1 (en) PHARMACEUTICAL COMPOSITION ON THE BASIS OF NANOPARTICLES OF DOCETAXEL-ALBUMIN, METHOD FOR ITS PREPARATION AND ITS APPLICATION
NO20180002A1 (en) Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors
EA201691918A1 (en) PHARMACEUTICAL COMPOSITIONS OF KINAZ INHIBITOR KINAZ OF THE RAF FAMILY, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE
PE20200600A1 (en) COMPOSITIONS AND METHODS TO PROMOTE HAIR GROWTH WITH MPC INHIBITORS
MX2021006724A (en) Haloallylamine compounds and application thereof.
CL2019001746A1 (en) Aromatic carboxylic acid amides
WO2017165822A8 (en) Small molecule inhibitor of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
ECSP20055797A (en) METHODS AND COMPOSITIONS TO TREAT CHRONIC PULMONARY DISEASES
EA201890075A1 (en) INJECTABLE PHARMACEUTICAL COMPOSITIONS LEFAMULIN
MX2019002047A (en) Methods and compositions for treating cutaneous fungal infections.
PH12016500738A1 (en) Formulation for gonadotropins
BR112017014914A2 (en) combined therapy for pulmonary hypertension
EA202091561A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING PHARMACEUTICALLY ACCEPTABLE ACID-ADDITIVE LENALIDOMIDE SALT
BR112015019524A8 (en) combination of a compound [i] with a taxane, method of producing an anticancer effect, use of a compound [i] in combination with a taxane, pharmaceutical composition and cancer treatment kit
EA201991341A1 (en) Phenytoin FOR LOCAL USE FOR TREATMENT OF PERIPHERAL NEUROPATHIC PAIN
MX2019000006A (en) Compositions for the treatment of ischemic ulcers and stretch marks.